Daten aus dem Cache geladen. Pregabalin for neuropathic pain in adults | Webyourself Social...

Pregabalin for neuropathic pain in adults

0
3K

Pregabalin for neuropathic pain in adults

We included 45 studies lasting 2 to 16 weeks, with 11,906 participants ‐ 68% from 31 new studies. Oral Pregabalin doses of 150 mg, 300 mg, and 600 mg daily were compared with placebo. Postherpetic neuralgia, painful diabetic neuropathy, and mixed neuropathic pain predominated (85% of participants). High risk of bias was due mainly to small study size (nine studies), but many studies had unclear risk of bias, mainly due to incomplete outcome data, size, and allocation concealment.

Postherpetic neuralgia: More participants had at least 30% pain intensity reduction with pregabalin 300 mg than with placebo (50% vs 25%; RR 2.1 (95% confidence interval (CI) 1.6 to 2.6); NNTB 3.9 (3.0 to 5.6); 3 studies, 589 participants, moderate‐quality evidence), and more had at least 50% pain intensity reduction (32% vs 13%; RR 2.5 (95% CI 1.9 to 3.4); NNTB 5.3 (3.9 to 8.1); 4 studies, 713 participants, moderate‐quality evidence). More participants had at least 30% pain intensity reduction with pregabalin 600 mg than with placebo (62% vs 24%; RR 2.5 (95% CI 2.0 to 3.2); NNTB 2.7 (2.2 to 3.7); 3 studies, 537 participants, moderate‐quality evidence), and more had at least 50% pain intensity reduction (41% vs 15%; RR 2.7 (95% CI 2.0 to 3.5); NNTB 3.9 (3.1 to 5.5); 4 studies, 732 participants, moderate‐quality evidence). Somnolence and dizziness were more common with pregabalin than with placebo (moderate‐quality evidence): somnolence 300 mg 16% versus 5.5%, 600 mg 25% versus 5.8%; dizziness 300 mg 29% versus 8.1%, 600 mg 35% versus 8.8%.

Painful diabetic neuropathy: More participants had at least 30% pain intensity reduction with pregabalin 300 mg than with placebo (47% vs 42%; RR 1.1 (95% CI 1.01 to 1.2); NNTB 22 (12 to 200); 8 studies, 2320 participants, moderate‐quality evidence), more had at least 50% pain intensity reduction (31% vs 24%; RR 1.3 (95% CI 1.2 to 1.5); NNTB 22 (12 to 200); 11 studies, 2931 participants, moderate‐quality evidence), and more had PGIC much or very much improved (51% vs 30%; RR 1.8 (95% CI 1.5 to 2.0); NNTB 4.9 (3.8 to 6.9); 5 studies, 1050 participants, moderate‐quality evidence). More participants had at least 30% pain intensity reduction with pregabalin 600 mg than with placebo (63% vs 52%; RR 1.2 (95% CI 1.04 to 1.4); NNTB 9.6 (5.5 to 41); 2 studies, 611 participants, low‐quality evidence), and more had at least 50% pain intensity reduction (41% vs 28%; RR 1.4 (95% CI 1.2 to 1.7); NNTB 7.8 (5.4 to 14); 5 studies, 1015 participants, low‐quality evidence). Somnolence and dizziness were more common with pregabalin than with placebo (moderate‐quality evidence): somnolence 300 mg 11% versus 3.1%, 600 mg 15% versus 4.5%; dizziness 300 mg 13% versus 3.8%, 600 mg 22% versus 4.4%.

Buscar
Categorías
Read More
Other
Textured Butter Market growth at a rate of 6.05% in the forecast period of 2021 to 2028.
The Textured Butter Market sector is undergoing rapid transformation, with significant...
By Tweety Chincholkar 2025-03-18 06:47:46 0 15
Other
Fluff Pulp Procurement Market Key Developments Trends, Analysis and Forecasts to 2030
Introduction The fluid milk procurement market is an essential segment within the dairy industry,...
By Diksha Pote 2024-06-05 10:52:05 0 550
Health
Gummy Gratification: People’s Keto Gummies [AU, NZ, UK, IE, ZA] Delights for a Sugar-Free Treat
 Introduction: In the dynamic world of health and wellness, ketogenic diets have gained...
By RevealCBD Gummies 2023-11-17 11:44:58 0 1K
Other
Discover Jaisalmer's Vibrant Culture: Event and Festival Tour with Marvin Desert Camp
Jaisalmer, a city located in the Indian state of Rajasthan, is known for its stunning desert...
By Marvin Desert Camp 2023-04-10 09:10:41 0 2K
Health
Smarter Hearing in 2025 AI Bone Conduction Hearing Aids Leading the Way
The world of hearing healthcare is on the cusp of a significant transformation, driven by the...
By Sophia Grant 2025-02-21 06:49:25 0 35